CA2822683C - Bepotastine compositions - Google Patents
Bepotastine compositions Download PDFInfo
- Publication number
- CA2822683C CA2822683C CA2822683A CA2822683A CA2822683C CA 2822683 C CA2822683 C CA 2822683C CA 2822683 A CA2822683 A CA 2822683A CA 2822683 A CA2822683 A CA 2822683A CA 2822683 C CA2822683 C CA 2822683C
- Authority
- CA
- Canada
- Prior art keywords
- concentration
- composition
- bepotastine
- rhinitis
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161429721P | 2011-01-04 | 2011-01-04 | |
| US61/429,721 | 2011-01-04 | ||
| PCT/US2012/020028 WO2012094283A2 (en) | 2011-01-04 | 2012-01-03 | Bepotastine compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2822683A1 CA2822683A1 (en) | 2012-07-12 |
| CA2822683C true CA2822683C (en) | 2015-05-12 |
Family
ID=46457931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2822683A Active CA2822683C (en) | 2011-01-04 | 2012-01-03 | Bepotastine compositions |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20120323178A1 (es) |
| EP (1) | EP2736491B1 (es) |
| JP (1) | JP5683719B2 (es) |
| KR (1) | KR101546596B1 (es) |
| CN (1) | CN103269687B (es) |
| AU (1) | AU2012204557B2 (es) |
| BR (1) | BR112013017183A2 (es) |
| CA (1) | CA2822683C (es) |
| ES (1) | ES2626134T3 (es) |
| MX (1) | MX337775B (es) |
| PL (1) | PL2736491T3 (es) |
| WO (1) | WO2012094283A2 (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013008244A8 (pt) * | 2010-10-06 | 2018-02-14 | Bausch & Lomb | composições de bepotastina |
| US8765725B2 (en) | 2012-05-08 | 2014-07-01 | Aciex Therapeutics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
| AU2013259872B2 (en) | 2012-05-08 | 2018-06-28 | Nicox Ophthalmics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
| US9815865B2 (en) | 2013-01-07 | 2017-11-14 | Nicox Ophthalmics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
| US11554229B2 (en) | 2013-03-26 | 2023-01-17 | OptiNose Inc. | Nasal administration |
| PL2978482T3 (pl) * | 2013-03-26 | 2022-10-03 | Optinose As | Podawanie donosowe |
| US9370483B2 (en) | 2013-09-13 | 2016-06-21 | Glenmark Specialty S.A. | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
| HRP20211515T1 (hr) * | 2013-09-13 | 2021-12-24 | Glenmark Specialty S.A. | Stabilni farmaceutski pripravak u fiksnoj dozi koji sadrži mometazon i olopatadin, namijenjen nazalnoj primjeni |
| US9937189B2 (en) | 2013-09-13 | 2018-04-10 | Glenmark Specialty S.A. | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
| US10016443B2 (en) | 2013-10-04 | 2018-07-10 | Glenmark Specialty S.A. | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
| US10758550B2 (en) | 2013-10-04 | 2020-09-01 | Glenmark Specialty S.A. | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
| US10548907B2 (en) | 2013-10-04 | 2020-02-04 | Glenmark Specialty S.A. | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
| CN112773808A (zh) | 2013-10-04 | 2021-05-11 | 格兰马克专业公司 | 使用莫米松和奥洛他定的组合治疗过敏性鼻炎 |
| US10653661B2 (en) | 2013-10-04 | 2020-05-19 | Glenmark Specialty S.A. | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
| CN103816121B (zh) * | 2014-03-07 | 2016-01-20 | 上海现代药物制剂工程研究中心有限公司 | 苯磺酸贝他斯汀鼻腔喷雾剂及其制备方法 |
| US9561177B2 (en) | 2014-03-14 | 2017-02-07 | Adapt Pharma Limited | Nasal drug products and methods of their use |
| US10085937B2 (en) | 2014-03-14 | 2018-10-02 | Adapt Pharma Limited | Nasal drug products and methods of their use |
| JP6945614B2 (ja) * | 2014-03-26 | 2021-10-06 | オプティノーズ アズ | 経鼻投与 |
| WO2015183047A1 (ko) * | 2014-05-30 | 2015-12-03 | 동아에스티 주식회사 | 베포타스틴과 글리세릴베헤네이트를 포함하는 약제학적 제제 |
| US10722510B2 (en) | 2014-07-08 | 2020-07-28 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
| US11135155B2 (en) | 2014-07-08 | 2021-10-05 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
| US11679210B2 (en) | 2014-10-03 | 2023-06-20 | Glenmark Specialty S.A. | Dispensing device and pharmaceutical composition for the treatment of rhinitis |
| US9980975B2 (en) | 2015-01-22 | 2018-05-29 | Ems S.A. | Dosage forms containing fluticasone propionate for the treatment of inflammatory conditions of the esophagus |
| US20170189352A1 (en) | 2015-03-13 | 2017-07-06 | Par Pharmaceutical, Inc. | Epinephrine formulations |
| US9119876B1 (en) | 2015-03-13 | 2015-09-01 | Par Pharmaceutical, Inc. | Epinephrine formulations |
| JP7106852B2 (ja) * | 2016-12-20 | 2022-07-27 | 大正製薬株式会社 | 懸濁型外用液剤 |
| EP3512522B1 (en) * | 2017-09-02 | 2025-11-12 | IVIEW Therapeutics, Inc. | In situ gel-forming pharmaceutical compositions and uses thereof for sinus diseases |
| SG11202112592YA (en) * | 2018-02-23 | 2021-12-30 | Glenmark Specialty Sa | Treatment of allergic rhinitis in pediatric subjects using a combination of mometasone and olopatadine |
| US10653646B2 (en) | 2018-03-23 | 2020-05-19 | Nevakar Inc. | Epinephrine compositions and containers |
| US12303635B2 (en) | 2018-04-16 | 2025-05-20 | Glenmark Specialty S.A. | Dispensing device and pharmaceutical composition for the treatment of rhinitis |
| JPWO2019235616A1 (ja) * | 2018-06-08 | 2021-06-17 | 東興薬品工業株式会社 | フルチカゾンフランカルボン酸エステル点鼻組成物 |
| EP3725298A1 (en) | 2019-04-16 | 2020-10-21 | Faes Farma, S.A. | Stable and preserved pharmaceutical compositions of bilastine |
| US20210283074A1 (en) * | 2020-03-16 | 2021-09-16 | Nasus Pharma Ltd. | Polymeric Compositions for Intranasal Administration |
| EP4216952A4 (en) * | 2020-09-24 | 2024-11-20 | NFlection Therapeutics, Inc. | TREATMENT OF COGNITIVE DYSFUNCTION WITH PYRROLOPYRIDINE-ANILINE COMPOUNDS |
| CN117954002B (zh) * | 2024-01-05 | 2024-10-22 | 苏州腾迈医药科技有限公司 | 分子对关系的展示方法及装置、介质 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8902300D0 (en) | 1989-02-02 | 1989-03-22 | Bryce Smith Derek | Antirhinoviral preparations |
| BR9709650A (pt) * | 1996-06-04 | 1999-08-10 | Procter & Gamble | Aerosol nasal contendo um esteróide intransal e um anti-histamínico |
| CN1222852A (zh) * | 1996-06-04 | 1999-07-14 | 普罗克特和甘保尔公司 | 含鼻内类固醇和抗组胺剂的鼻喷雾剂 |
| US5976573A (en) * | 1996-07-03 | 1999-11-02 | Rorer Pharmaceutical Products Inc. | Aqueous-based pharmaceutical composition |
| TW486475B (en) | 1996-12-26 | 2002-05-11 | Ube Industries | Acid addition salt of optically active piperidine compound and process for preparing the same |
| GB9918559D0 (en) * | 1999-08-07 | 1999-10-06 | Glaxo Wellcome Kk | Novel pharmaceutical formulation |
| DE19947234A1 (de) * | 1999-09-30 | 2001-04-05 | Asta Medica Ag | Neue Kombination von Loteprednol und Antihistaminika |
| US6565832B1 (en) * | 2000-01-31 | 2003-05-20 | Schering-Plough Healthcare Products, Inc. | Spray composition with reduced dripping |
| US20040176359A1 (en) * | 2001-02-20 | 2004-09-09 | University Of Kentucky Research Foundation | Intranasal Benzodiazepine compositions |
| KR20040033286A (ko) * | 2001-05-31 | 2004-04-21 | 파마시아 코포레이션 | 선택적인 사이클로옥시게나제-2 억제제 및 1가 알콜을포함하는 피부-침투성 조성물 |
| AU2002366567B2 (en) * | 2001-12-05 | 2006-11-16 | Alcon, Inc. | Use of an H1 antagonist and a safe steroid to treat rhinitis |
| WO2003101434A2 (en) * | 2001-12-21 | 2003-12-11 | Sampad Bhattacharya | Intranasal pharmaceutical compositions comprising an antihistamine and a leukotriene inhibitor |
| ATE528003T1 (de) * | 2002-07-31 | 2011-10-15 | Senju Pharma Co | Wässrige, flüssigkeitszubereitungen und lichtstabilisierte wässrige flüssigkeitszubereitungen |
| DE60333205D1 (de) * | 2002-08-30 | 2010-08-12 | Nycomed Gmbh | Histaminika zur behandlung von allergischer rhinitis |
| MXPA06003320A (es) * | 2003-09-24 | 2006-06-08 | Combinatorx Inc | Regimenes terapeuticos para administrar combinaciones de farmacos. |
| WO2005030793A2 (en) * | 2003-09-24 | 2005-04-07 | Millennium Pharmaceuticals, Inc. | Antibodies which bind human cxcr3 |
| US20050112199A1 (en) * | 2003-09-24 | 2005-05-26 | Mahesh Padval | Therapeutic regimens for administering drug combinations |
| DK2377557T3 (en) * | 2004-11-24 | 2017-02-06 | Meda Pharmaceuticals Inc | Compositions comprising azelastine and methods for its use |
| DK1919450T3 (da) * | 2005-09-01 | 2014-09-15 | Meda Ab | Antihistamin- og corticosteroidholdig liposomsammensætning og dens anvendelse til fremstilling af et lægemiddel til behandling af rhinitis og beslægtede lidelser |
| GB0615108D0 (en) * | 2006-07-28 | 2006-09-06 | Glaxo Group Ltd | Novel formulations |
| US20090325917A1 (en) * | 2006-10-19 | 2009-12-31 | Cipla Limited | Pharmaceutical Compositions and Nasal Spray Incorporating Anhydrous Mometasone Furoate |
| KR100878698B1 (ko) * | 2007-04-05 | 2009-01-13 | 한미약품 주식회사 | 결정형의 베포타스틴 금속염 수화물, 이의 제조방법 및이를 포함하는 약학 조성물 |
| TW200902025A (en) | 2007-04-11 | 2009-01-16 | Alcon Res Ltd | Use of an inhibitor of TNF α plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis |
| ES2493641T3 (es) * | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Administración nasal de soluciones acuosas de corticosteroides |
| KR20090061972A (ko) | 2007-12-12 | 2009-06-17 | 한미약품 주식회사 | 베포타스틴 ｐ-톨루엔술폰산염의 결정형, 이의 제조방법 및이를 포함하는 약학 조성물 |
| EP2340023A1 (en) * | 2008-09-02 | 2011-07-06 | Glaxo Group Limited | The trpvl antagonist sb-705498 for treating rhinitis |
| JP2010195716A (ja) | 2009-02-25 | 2010-09-09 | Takeda Chem Ind Ltd | 点鼻睡眠導入剤 |
| BR112013008244A8 (pt) * | 2010-10-06 | 2018-02-14 | Bausch & Lomb | composições de bepotastina |
-
2012
- 2012-01-03 EP EP12732455.6A patent/EP2736491B1/en not_active Not-in-force
- 2012-01-03 WO PCT/US2012/020028 patent/WO2012094283A2/en not_active Ceased
- 2012-01-03 KR KR1020137020553A patent/KR101546596B1/ko not_active Expired - Fee Related
- 2012-01-03 US US13/505,438 patent/US20120323178A1/en not_active Abandoned
- 2012-01-03 JP JP2013548453A patent/JP5683719B2/ja not_active Expired - Fee Related
- 2012-01-03 MX MX2013007409A patent/MX337775B/es active IP Right Grant
- 2012-01-03 CA CA2822683A patent/CA2822683C/en active Active
- 2012-01-03 CN CN201280004305.9A patent/CN103269687B/zh not_active Expired - Fee Related
- 2012-01-03 AU AU2012204557A patent/AU2012204557B2/en not_active Ceased
- 2012-01-03 BR BR112013017183A patent/BR112013017183A2/pt not_active IP Right Cessation
- 2012-01-03 ES ES12732455.6T patent/ES2626134T3/es active Active
- 2012-01-03 PL PL12732455T patent/PL2736491T3/pl unknown
- 2012-05-02 US US13/462,466 patent/US10736841B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112013017183A2 (pt) | 2017-07-25 |
| EP2736491A4 (en) | 2014-07-09 |
| JP5683719B2 (ja) | 2015-03-11 |
| CA2822683A1 (en) | 2012-07-12 |
| PL2736491T3 (pl) | 2017-09-29 |
| KR101546596B1 (ko) | 2015-08-21 |
| JP2014501779A (ja) | 2014-01-23 |
| WO2012094283A2 (en) | 2012-07-12 |
| CN103269687B (zh) | 2016-09-14 |
| EP2736491A2 (en) | 2014-06-04 |
| US20120323178A1 (en) | 2012-12-20 |
| KR20130135296A (ko) | 2013-12-10 |
| US10736841B2 (en) | 2020-08-11 |
| AU2012204557A1 (en) | 2013-05-02 |
| ES2626134T3 (es) | 2017-07-24 |
| AU2012204557B2 (en) | 2015-05-14 |
| EP2736491B1 (en) | 2017-04-05 |
| MX337775B (es) | 2016-03-18 |
| US20120255544A1 (en) | 2012-10-11 |
| CN103269687A (zh) | 2013-08-28 |
| MX2013007409A (es) | 2013-11-01 |
| WO2012094283A3 (en) | 2012-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2822683C (en) | Bepotastine compositions | |
| US20250262305A1 (en) | Intranasal epinephrine formulations and methods for the treatment of disease | |
| JP5759553B2 (ja) | ベポタスチン組成物 | |
| US10517880B2 (en) | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine | |
| EP3678649B1 (en) | Intranasal epinephrine formulations and methods for the treatment of disease | |
| US20170333449A1 (en) | Treatment of allergic rhinitis using a combination of mometasone and olopatadine | |
| EP3755375B1 (en) | Treatment of allergic rhinitis in pediatric subjects using a combination of mometasone and olopatadine | |
| US20250262173A1 (en) | Intranasal epinephrine formulations and methods of use | |
| RU2798030C2 (ru) | Лечение аллергического ринита у субъектов детской возрастной категории с применением комбинации мометазона и олопатадина | |
| HK40033829A (en) | Treatment of allergic rhinitis in pediatric subjects using a combination of mometasone and olopatadine | |
| HK40033829B (en) | Treatment of allergic rhinitis in pediatric subjects using a combination of mometasone and olopatadine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20130620 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD Year of fee payment: 13 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241219 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241219 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241219 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD Year of fee payment: 14 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251217 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251217 |